254P - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer (BC): A prospective clinical study

Abstract

BackgroundSystemic chemotherapy (SC) has a negative effect on ovarian functions. The aim of this study is to investigate the effect of SC on anti-müllerian hormone (AMH) levels, antral follicle counts (AFC) and ovarian volumes (MOV) in patients with BC. MethodsThe demographic, clinical and pathological features of premenopausal breast cancer (BC) patients who were operated in the Istanbul Florence Nightingale Hospital were recorded. AMH levels, AFC and MOV measurements were performed before and after adjuvant SC in 3-month periods. The patients who did not have menstruel cycles for 6 months or longer had been classified as chemotherapy induced amenorrhea (CIA). The effects of different chemotherapy regimens on AMH, AFC and MOV in terms menstruel cycles resumption and CIA were investigated. ResultsSeventy one patients were eligible for the study, and median age of them was 38 years (ranged from 23 to 51 years). Median follow-up was 37 months (ranged from 20 to 51 months), CIA developed in 62% of patients. AMH, AFC, and MOV significantly decreased one year after SC (p<0.0001). AMH before chemotherapy (median: 1,520 vs 0,755, p=0.001), at the end of first year (median: 0,073 vs 0,010ng/ml, p=0.030) and pre-treatment AFC (median12 vs 4,50, p=0.026) was lower in patients with CIA comparing those without CIA. In multivariate logistic regression analysis, AMH levels (OR:0.273, 95%: 0.102 – 0.733, p=0.010) and AFC (OR: 1,180, 95% CI; 1,016-1,369, p=0.030) before SC were the most valuable and earliest factors to predict CIA. There were no significant relationships between age of the patients (≤30vs>30 ), BMI (30vs> 30), SC regimen and number of cycles (4 vs>4) and CIA (p>0.05).Table254P muitivariet analyses with logistic regrettion for CIATableUNIVARIETMULTIVARIETOR95% CIOR95% CIER0,190,038-0,8910,0350,0020,000- 0,1110,002HER 20.800,435-2,9361,130ALND PERFORMED1,750,653-4,7020,265AMH-10,640,454-0,9140,0140,2730,102- 0,7330,010AMH-50,230,063-0,8120,0230,0090,000- 0,7540,037AFC-10,870,780-0,9610,0070,7350,572- 0,9440,016AFC-50,930,741-1,1650,527MOV-11,000,987-1,0210,686MOV-50,980,854-1,1580,790TAXANE/W&İTHOUTTAXANE0,710,267-1,9100,503TC/AC0,850,209-3,4910,825AGE 354,661,613-13,4980,004CHEMONUMBER0,240,080-0,7660,017BMI 252,570,929-7,1180,069 ConclusionsSC significantly decreases AMH and AFC values independently of chemotherapeutic agents in patients with BC. The low AMH levels and less AFC before SC may predict CIA. Legal entity responsible for the studyİstanbul Demiroğlu Bilim University. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.